Per slide 10, China is key with 90M HBV patients (good to see ASMB opened China-specific office in 2015) then you have 1.5M patients in U.S.; 5M in Europe; 2M in South Korea; and just over 1M in Japan. These figures outnumber HCV in those countries and dramatically so if China is included.
Also, slide 103 notes that 2017 sales for HBV drugs in those countries were $2.5B for non-curative and mostly generic drugs. I don't think it's hard to imagine how that number would dramatically rise if there were a branded, curative drug available.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.